Emoksipin

General characteristics. Structure:

Active ingredient: 150 mg of an emoksipin (metiletilpiridinol of a hydrochloride).

Excipients: 1 M hydroxide sodium solution, water for injections.

The medicine having favorable effect on a nervous system, angioprotektorny action and improving microcirculation.

Pharmacological properties:

Pharmacodynamics. Emoksipin exerts beneficial effect on system of a blood coagulation: slows down aggregation of thrombocytes, reduces the general index of coagulation, extends a blood clotting time. Strengthens process of a fibrinolysis. Reduces viscosity of blood, permeability of a vascular wall. Stabilizes membranes of cells of blood vessels and erythrocytes, increases resistance of erythrocytes to a mechanical injury and hemolysis. Has angioprotektorny properties. Improves microcirculation.

Effectively inhibits free radical oxidation of lipids of biomembranes, increases activity of antioxidant enzymes. Stabilizes R-450 cytochrome, possesses anti-toxic action. In the extreme situations which are followed by strengthening of peroxide oxidation of lipids and a hypoxia optimizes biopower processes.

Emoksipin reduces symptoms of cerebral haemo dysfunction. Increases resistance of a brain to a hypoxia and ischemia. At disturbances of cerebral circulation (ischemic and hemorrhagic) promotes correction of vegetative dysfunctions, facilitates recovery of integrative activity of a brain, improves mnestichesky functions.
 
Expands coronary vessels, reduces ischemic injury of a myocardium. At a myocardial infarction limits necrosis center size, accelerates reparative processes, contributes to normalization of metabolism of a myocardium. Exerts beneficial effect on the clinical course of a myocardial infarction, reducing the frequency of development of an acute heart failure. Promotes regulation of oxidation-reduction system at a circulatory unefficiency.

Pharmacokinetics. At intravenous administration in a dose of 10 mg/kg the period of semi-elimination of T1/2 makes 18 min.; the general clearance of CI - 0,2 l/min; the seeming volume of distribution of Vd - 5,2 l.

Medicine quickly gets into bodies and fabrics where there is its deposition and metabolism. 5 metabolites of an emoksipin presented by the dialkylated and conjugated products of its transformation are revealed. Metabolites of an emoksipin are excreted by kidneys. In significant amounts in a liver 2-etil-6-metil-Z-oksipiridin-fosfat is found.

At morbid conditions, for example, in case of coronary occlusion, the pharmacokinetics of an emoksipin changes. Removal speed decreases, the time spent of an emoksipin in a circulatory bed increases that can be connected with its return receipt from depot, including from an ischemic myocardium.

Indications to use:

In neurology and neurosurgery in complex therapy: a hemorrhagic stroke, an ischemic stroke in the pool of an internal carotid artery and in vertebrobazilyarny system, passing disturbances of cerebral circulation, chronic insufficiency of cerebral circulation, the craniocereberal injury which is followed by brain bruises; the postoperative period at the patients with a craniocereberal injury operated concerning Epi - the subdural and intracerebral hematomas which are combined with brain bruises; before - and the postoperative period at patients with arterial aneurisms and arteriovenous malformation of vessels of a brain.

In cardiology in complex therapy: acute myocardial infarction, prevention of "reperfusion syndrome", unstable stenocardia.

Route of administration and doses:

Doses, duration of a course of treatment are defined individually. In neurology and нейрохирургииэмоксипин apply intravenously kapelno in a daily dose 5 - 10 mg/kg within 10 - 12 days. Before introduction эмоксипин part in 200 ml of solution of sodium of chloride isotonic. Enter with a speed of 20 - 30 thaws a minute. In the subsequent        2 - 3 times a day within 10 - 30 days pass to intramuscular introduction 2 - 10 ml of solution of 30 mg/ml of an emoksipin (60 - 300 mg).

In kardiologiinachinat with intravenous drop (20 - 40 drops a minute) introduction   of 20 - 30 ml of solution of 30 mg/ml of an emoksipin (600 - 900 mg) to 200 ml of solution of sodium of chloride of isotonic 1 - 3 time a day within 5 - 15 days depending on the course of a disease, with the subsequent transition to intramuscular introduction of 2 - 10 ml of solution of 30 mg/ml of an emoksipin (60 - 300 mg) 2 - 3 times a day within 10 - 30 days.

Treatment emoksipiny, in case of its intravenous and intramuscular administration, should be carried out under control of arterial pressure and a functional condition of coagulant and anticoagulative systems of blood.

Features of use:

It is necessary to control constantly during treatment the ABP and coagulability of blood.

Pregnancy and lactation. Use during pregnancy is contraindicated. Use of medicine in the period of a lactation (breastfeeding) according to indications is possible if the expected effect of therapy exceeds potential risk for a fruit.

Influences on ability of control of vehicles and potentially dangerous mechanisms. Medicine does not influence ability to control of vehicles and the machine equipment.

Side effects:

Excitement, drowsiness, increase in arterial pressure, reaction in an injection site (a burning sensation on the vein course, pain, an itch). The headache, pain in heart are in rare instances possible, persons with chronic pathology of digestive organs have a nausea, discomfort in epigastric area. At predisposition to allergic reactions emergence of an itch and erubescence are in rare instances observed.

Interaction with other medicines:

Negative manifestations at use of an emoksipin against the background of therapy by other medicines are not described.

α - Tocopherol acetate exponentiates antioxidant effect of an emoksipin.

Emoksipin is not recommended to mix with other injection means in one syringe.

Contraindications:

The increased individual sensitivity to medicine, pregnancy, the lactation period, children up to 18 years.

Overdose:

At overdose strengthening of expressiveness of side effects of medicine is possible.

Simptomy:povysheny arterial pressure, excitement or drowsiness, a headache, pain in heart, nausea, discomfort in epigastric area. Disturbance of coagulability of blood is possible.

Lecheniye:simptomatichesky therapy, is not present a specific antidote.

Storage conditions:

To store in the place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity. 2 years. Not to use after a period of validity.

Issue conditions:

According to the recipe

Packaging:

On 5 ml in bottles. On 10 bottles together with the application instruction place in a box from a cardboard.